Table 2 Details of Salvage therapy
From: Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Subgroup | Number (55) |
|---|---|
Relapse | |
Nil | 7 |
Yes | 48 |
Repeat Craniotomy | |
No relapse | 7 |
Craniotomy | 18 |
Nil | 30 |
Re-irradiation | |
No relapse | 7 |
ReRT | 16 |
Nil | 32 |
BEV use | |
No relapse | 7 |
Pseudoprogression | 5 |
Relapse | 28 |
Nil | 15 |
Timing of BEV at Relapse | (n=28) |
First relapse | 4 |
Second relapse | 8 |
Third relapse | 16 |
Number of BEV cycles at Relapse | |
Median | 8 |
Range | 1-25 |